FluoGuide has been granted Fast Track designation by FDA for its intraoperative imaging agent FG001. The designation applies to the surgical resection of high-grade glioma, a severe brain cancer with a high unmet medical need. This regulatory milestone follows the recent clearance of the company's Investigational New Drug application and provides opportunities for expedited review. BioStock contacted CEO Morten Albrechtsen to learn more.
Read the full article at biostock.se:
https://biostock.se/en/2026/03/fluoguide-erhaller-fda-fast-track-status-for-fg001-vid-hoggradigt-gliom/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/